Medigen Vaccine Biologics Asset Resilience Ratio
Medigen Vaccine Biologics asset resilience ratio. Medigen Vaccine Biologics (6547) has an Asset Resilience Ratio of 37.48% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6547 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Medigen Vaccine Biologics (2014–2025)
Asset resilience ratio of Medigen Vaccine Biologics from 2014 to 2025. This chart shows how Medigen Vaccine Biologics's Asset Resilience Ratio has changed over time. Read how much debt does Medigen Vaccine Biologics carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Medigen Vaccine Biologics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 6547 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.78 Billion | 37.48% |
| Total Liquid Assets | NT$1.78 Billion | 37.48% |
Asset Resilience Insights
- Very High Liquidity: Medigen Vaccine Biologics maintains exceptional liquid asset reserves at 37.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Medigen Vaccine Biologics Industry Peers by Asset Resilience Ratio
Compare Medigen Vaccine Biologics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 1.28% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 10.35% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
Medigen Vaccine Biologics Asset Resilience Ratio by Year (2014–2025)
Medigen Vaccine Biologics asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Medigen Vaccine Biologics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.11% | NT$1.18 Billion ≈ $37.32 Million |
NT$3.93 Billion ≈ $123.94 Million |
+2.61pp |
| 2024-12-31 | 27.50% | NT$1.20 Billion ≈ $37.81 Million |
NT$4.36 Billion ≈ $137.49 Million |
-11.96pp |
| 2023-12-31 | 39.46% | NT$2.40 Billion ≈ $75.75 Million |
NT$6.09 Billion ≈ $191.95 Million |
-1.81pp |
| 2022-12-31 | 41.28% | NT$3.03 Billion ≈ $95.55 Million |
NT$7.35 Billion ≈ $231.49 Million |
+25.18pp |
| 2021-12-31 | 16.10% | NT$853.10 Million ≈ $26.88 Million |
NT$5.30 Billion ≈ $166.95 Million |
+14.58pp |
| 2020-12-31 | 1.52% | NT$53.17 Million ≈ $1.68 Million |
NT$3.49 Billion ≈ $109.98 Million |
-0.81pp |
| 2019-12-31 | 2.34% | NT$53.23 Million ≈ $1.68 Million |
NT$2.28 Billion ≈ $71.74 Million |
-20.68pp |
| 2018-12-31 | 23.02% | NT$502.52 Million ≈ $15.83 Million |
NT$2.18 Billion ≈ $68.78 Million |
+22.88pp |
| 2017-12-31 | 0.14% | NT$2.97 Million ≈ $93.57K |
NT$2.14 Billion ≈ $67.31 Million |
-1.15pp |
| 2016-12-31 | 1.29% | NT$23.46 Million ≈ $739.02K |
NT$1.82 Billion ≈ $57.26 Million |
+0.06pp |
| 2015-12-31 | 1.23% | NT$20.32 Million ≈ $640.19K |
NT$1.65 Billion ≈ $52.09 Million |
-32.62pp |
| 2014-12-31 | 33.85% | NT$411.20 Million ≈ $12.96 Million |
NT$1.21 Billion ≈ $38.27 Million |
-- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more